Diagnostic and prognostic markers in gliomas

被引：41

作者：

Ducray, Francois ^{[1
]}

El Hallani, Soufiane ^{[2
]}

Idbaih, Ahmed ^{[2
]}

机构：

[1] Univ Lyon 1, Hop Neurol, Serv Neurol B, INSERM,U842, F-69365 Lyon, France

[2] Univ Paris 06, Grp Hosp Pitie Salpetriere, Serv Neurol Mazarin, INSERM,U711, Paris, France

来源：

CURRENT OPINION IN ONCOLOGY | 2009年 / 21卷 / 06期

关键词：

1p/19q codeletion; BRAF; glioma; isocitrate dehydrogenase 1; O-6-methylguanine-DNA methyltransferase; MGMT PROMOTER METHYLATION; LOW-GRADE GLIOMAS; IDH1; CODON; 132; 1P/19Q LOSS; ANAPLASTIC OLIGODENDROGLIOMAS; PHASE-III; ADJUVANT TEMOZOLOMIDE; MAPK PATHWAY; GLIOBLASTOMA; GENE;

D O I：

10.1097/CCO.0b013e32833065a7

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose of review This review summarizes recent studies on diagnostic and prognostic markers in gliomas such as the BRAF fusion gene in pilocytic astrocytomas and 1p/19q codeletion, O-6-methylguanine-DNA methyltransferase status and isocitrate dehydrogenase 1 (IDH1)/IDH2 mutations in diffuse gliomas. Recent findings In pilocytic astrocytomas, the BRAF fusion gene has been recently identified as a specific and frequent event leading to potentially targetable mitogen-activated protein kinase pathway activation. In grade II/III gliomas and in glioblastomas, chromosome 1p/19q codeletion and O-6-methylguanine-DNA methyltransferase status remain the most important prognostic and predictive markers. Recently identified mutations in IDH1/IDH2, however, are specific for diffuse gliomas, occur frequently in grade II/III gliomas and are of prognostic value in grade III gliomas, as well in glioblastomas in which they characterize secondary glioblastomas. Summary Extensive molecular studies have enabled the discovery of new diagnostic and prognostic markers that are refining the histomolecular classification of gliomas.

引用

页码：537 / 542

页数：6

共 59 条

[1] Analysis of the IDH1 codon 132 mutation in brain tumors [J].

Balss, Joerg ;

Meyer, Jochen ;

Mueller, Wolf ;

Korshunov, Andrey ;

Hartmann, Christian ;

von Deimling, Andreas .

ACTA NEUROPATHOLOGICA, 2008, 116 (06) :597-602

[2] NOTCH2 Is Neither Rearranged nor Mutated in t(1;19) Positive Oligodendrogliomas [J].

Benetkiewicz, Magdalena ;

Idbaih, Ahmed ;

Cousin, Pierre-Yves ;

Boisselier, Blandine ;

Marie, Yannick ;

Criniere, Emmanuelle ;

Hoang-Xuan, Khe ;

Delattre, Jean-Yves ;

Sanson, Marc ;

Delattre, Olivier .

PLOS ONE, 2009, 4 (01)

[3] IDH1 Mutations at Residue p.R132 (IDH1R132) Occur Frequently in High-Grade Gliomas But Not in Other Solid Tumors [J].

Bleeker, Fonnet E. ;

Lamba, Simona ;

Leenstra, Sieger ;

Troost, Dirk ;

Hulsebos, Theo ;

Vandertop, W. Peter ;

Frattini, Milo ;

Molinari, Francesca ;

Knowles, Margaret ;

Cerrato, Aniello ;

Rodolfo, Monica ;

Scarpa, Aldo ;

Felicioni, Lara ;

Buttitta, Fiamma ;

Malatesta, Sara ;

Marchetti, Antonio ;

Bardelli, Alberto .

HUMAN MUTATION, 2009, 30 (01) :7-11

[4] Loss of NOTCH2 Positively Predicts Survival in Subgroups of Human Glial Brain Tumors [J].

Boulay, Jean-Louis ;

Miserez, Andre R. ;

Zweifel, Christian ;

Sivasankaran, Balasubramanian ;

Kana, Veronika ;

Ghaffari, Anthony ;

Luyken, Cordelia ;

Sabel, Michael ;

Zerrouqi, Abdessamad ;

Wasner, Morten ;

Van Meir, Erwin ;

Tolnay, Markus ;

Reifenberger, Guido ;

Merlo, Adrian .

PLOS ONE, 2007, 2 (06)

[5] MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients [J].

Brandes, Alba A. ;

Franceschi, Enrico ;

Tosoni, Alicia ;

Blatt, Valeria ;

Pession, Annalisa ;

Tallini, Giovanni ;

Bertorelle, Roberta ;

Bartolini, Stefania ;

Calbucci, Fabio ;

Andreoli, Alvaro ;

Frezza, Giampiero ;

Leonardi, Marco ;

Spagnolli, Federica ;

Ermani, Mario .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (13) :2192-2197

[6] Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: A prospective GICNO study [J].

Brandes, Alba A. ;

Tosoni, Alicia ;

Cavallo, Giovanna ;

Reni, Michele ;

Franceschi, Enrico ;

Bonaldi, Laura ;

Bertorelle, Roberta ;

Gardiman, Marina ;

Ghimenton, Claudio ;

Iuzzolino, Paolo ;

Pession, Annalisa ;

Blatt, Valeria ;

Ermani, Mario .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (29) :4746-4753

[7] Recurrence Pattern After Temozolomide Concomitant With and Adjuvant to Radiotherapy in Newly Diagnosed Patients With Glioblastoma: Correlation With MGMT Promoter Methylation Status [J].

Brandes, Alba A. ;

Tosoni, Alicia ;

Franceschi, Enrico ;

Sotti, Guido ;

Frezza, Giampiero ;

Amista, Pietro ;

Morandi, Luca ;

Spagnolli, Federica ;

Ermani, Mario .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (08) :1275-1279

[8] Oligodendrogliomas: Molecular Biology and Treatment [J].

Bromberg, Jacolien E. C. ;

van den Bent, Martin J. .

ONCOLOGIST, 2009, 14 (02) :155-163

[9] Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402 [J].

Cairncross, Gregory ;

Berkey, Brian ;

Shaw, Edward ;

Jenkins, Robert ;

Scheithauer, Bernd ;

Brachman, David ;

Buckner, Jan ;

Fink, Karen ;

Souhami, Luis ;

Laperierre, Normand ;

Mehta, Minesh ;

Curran, Walter .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) :2707-2714

[10] Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas [J].

Cairncross, JG ;

Ueki, K ;

Zlatescu, MC ;

Lisle, DK ;

Finkelstein, DM ;

Hammond, RR ;

Silver, JS ;

Stark, PC ;

Macdonald, DR ;

Ino, Y ;

Ramsay, DA ;

Louis, DN .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (19) :1473-1479

← 1 2 3 4 5 6 →